Will Junshi Bio's Loss-Making Headaches Ease With Landmark U.S. Drug Approval? - BeiGene (NASDAQ:BGNE), Coherus BioSciences (NASDAQ:CHRS)

Key Takeaways: Junshi Bio will receive milestone payments and 20% of sales of its PD-1 drug Toripalimab in the U.S., following the drug’s recent approval by the FDA The drug maker’s revenue fell 19% year-on-year in the first nine months of 2023, as its net loss narrowed to 1.41 billion yuan By Molly Wen

Related Keywords

India ,United States ,United Kingdom ,South Africa ,Canada ,Hong Kong ,China ,Chinese ,America ,Junshi Bio ,Coheru Toripalimab ,Molly Wen ,Shanghai Junshi Biosciences Co ,World Health Organization ,Revenue Booster ,Drug Administration ,Shanghai Junshi Biosciences ,Chinesea Share ,Southeast Asia ,Middle East ,North Africa ,Latin America ,